New triple therapy targets hard-to-treat liver metastases in colorectal cancer
NCT ID NCT07353268
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of an antibody drug (QL1706), a targeted therapy (fruquintinib), and short-course radiotherapy against standard third-line therapy in 76 adults with colorectal cancer that has spread to the liver and cannot be removed by surgery. The goal is to see if the new combo is safer and more effective at delaying cancer growth. Participants must have a specific tumor type (pMMR/MSS) and liver metastases at least 5 cm in size.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••